The Current Ratio as of September 2024 (TTM) for Kineta, Inc. (KA) is 0.14

According to Kineta, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 0.14. This represents a change of -75.01% compared to the average of 0.57 of the last 4 quarters.

Kineta, Inc. (KA) Historical Current Ratio (quarterly & annually)

How has KA Current Ratio performed in the past?

The mean historical Current Ratio of Kineta, Inc. over the last ten years is 4.92. The current 0.14 Current Ratio has changed 188.53% with respect to the historical average. Over the past ten years (40 quarters), KA's Current Ratio was at its highest in in the September 2020 quarter at 6.76. The Current Ratio was at its lowest in in the June 2024 quarter at 0.14.

Kineta, Inc. (KA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Kineta, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kineta, Inc. (KA) Average Current Ratio

How has KA Current Ratio performed in the past?

The current Current Ratio of Kineta, Inc. (KA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Kineta, Inc. (KA) Current Ratio vs. Peers

How is KA’s Current Ratio compared to its peers?

Kineta, Inc.’s Current Ratio is less than Rezolute, Inc. (11.82), less than Cyteir Therapeutics, Inc. (21.89), less than XOMA Corporation (8.71), less than Protagenic Therapeutics, Inc. (2.03), less than Tempest Therapeutics, Inc. (2.17), less than Candel Therapeutics, Inc. (1.62), less than MiNK Therapeutics, Inc. (0.93), less than Forte Biosciences, Inc. (2.82), less than AlloVir, Inc. (55.08), less than Dyadic International, Inc. (5.39), less than DiaMedica Therapeutics Inc. (17.82), less than Kintara Therapeutics, Inc. (5.04), less than Silo Pharma, Inc. (5.84), less than Protagenic Therapeutics, Inc. (2.03), less than Lumos Pharma, Inc. (4.23), less than Anebulo Pharmaceuticals, Inc. (5.32), less than Molecular Partners AG (14.58), less than Mineralys Therapeutics, Inc. (11.20), less than AN2 Therapeutics, Inc. (10.61), less than Pharvaris N.V. (18.45), less than PepGen Inc. (7.45),

Build a custom stock screener for Kineta, Inc. (KA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kineta, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kineta, Inc. (KA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kineta, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.